Back to Articles

We Analyzed 50 Peptide COAs. Here's What We Found.

May 8, 20266 min readTruPeptide Editorial

The Methodology

Over the past three months, we collected 50 Certificates of Analysis from across the peptide supply chain:

  • 18 COAs from US-based research peptide vendors
  • 14 COAs from licensed 503A compounding pharmacies
  • 10 COAs from international suppliers (China, India, Europe)
  • 8 COAs from 503B outsourcing facilities

We evaluated each COA against 8 quality criteria and cross-referenced results with publicly available community testing data where possible.

Important note: We did not independently test any products. This analysis evaluates the COA documents themselves — their completeness, verifiability, and consistency — not the actual purity of the products they describe.

The 8 Criteria We Evaluated

| # | Criterion | What It Means | |---|-----------|---------------| | 1 | Named third-party lab | Is the testing lab identified and contactable? | | 2 | Batch/lot number present | Can the COA be matched to a specific production run? | | 3 | HPLC chromatogram included | Is the raw purity data (the actual graph) shown? | | 4 | Mass spectrometry data | Is molecular identity confirmed, not just purity? | | 5 | Endotoxin testing | For injectables — is bacterial contamination tested? | | 6 | Sterility testing | For injectables — is the product confirmed sterile? | | 7 | Realistic purity values | Are results plausible (not suspiciously perfect)? | | 8 | Lab verifiable | Can the lab confirm they tested this batch? |

The Results

Overall Scores by Source Type

| Source Type | Avg. Criteria Met (of 8) | Range | |-------------|--------------------------|-------| | 503B outsourcing facilities | 7.6 / 8 | 7–8 | | 503A compounding pharmacies | 6.9 / 8 | 5–8 | | US research vendors | 4.2 / 8 | 1–7 | | International suppliers | 3.1 / 8 | 1–6 |

The Gap Is Stark

Licensed pharmacies (503A and 503B) consistently provided complete, verifiable COAs. Research vendors and international suppliers showed enormous variation — from excellent documentation rivaling pharmacy-grade to essentially worthless pieces of paper.

Key Findings

Finding 1: 34% of Research Vendor COAs Had No Named Lab

Of the 18 research vendor COAs we reviewed, 6 (34%) either had no lab name at all, listed a lab we couldn't verify existed, or used a generic "in-house testing" attribution. Without a named, contactable lab, a COA is essentially a self-reported claim.

Finding 2: Only 22% of Research Vendor COAs Included Mass Spec

HPLC tells you something is pure. Mass spectrometry tells you what it actually is. Only 4 of 18 research vendor COAs included mass spec data confirming molecular identity. This means 78% of research vendor COAs only confirm purity — not that the product is actually the peptide it claims to be.

By contrast, 100% of 503B facility COAs and 86% of 503A pharmacy COAs included mass spec confirmation.

Finding 3: Endotoxin and Sterility Testing Is Rare Outside Pharmacies

For injectable peptides, endotoxin and sterility testing are critical safety measures. Bacterial endotoxins can cause fever, sepsis, and death.

| Source Type | Endotoxin Testing | Sterility Testing | |-------------|-------------------|-------------------| | 503B facilities | 100% | 100% | | 503A pharmacies | 86% | 79% | | US research vendors | 11% | 6% | | International suppliers | 0% | 0% |

This is perhaps the most concerning finding. The vast majority of research-grade peptides sold for "research purposes" — but clearly used by humans — have never been tested for bacterial contamination.

Finding 4: Suspiciously Perfect Purity Is Common

We flagged COAs reporting exactly round purity numbers (99.0%, 98.0%) with zero identified impurities. Real analytical chemistry produces decimal results and detects trace impurities even in high-quality products.

  • 44% of research vendor COAs reported suspiciously round numbers
  • 20% of international supplier COAs reported exactly 99.0% with no impurity profile
  • 0% of pharmacy COAs had this issue — all reported realistic decimal values with identified trace impurities

Finding 5: The Best Research Vendors Match Pharmacy Quality

Not all research vendors are bad actors. The top-tier vendors in our sample (scoring 6–7 out of 8) provided COAs that were nearly indistinguishable from pharmacy-grade documentation:

  • Named, contactable third-party lab (typically Janoshik or Colmaric)
  • Batch-specific testing with unique chromatograms
  • Both HPLC and mass spec data
  • Realistic purity values with identified impurities

These vendors represent the gold standard for the research market. They're also typically the most expensive research vendors — quality documentation costs money.

Finding 6: International Suppliers Are the Highest Risk

The 10 international supplier COAs in our sample scored lowest across every criterion. Common issues:

  • Labs listed that don't appear to exist
  • COAs in English from Chinese suppliers with formatting inconsistencies suggesting translation/fabrication
  • Identical chromatogram images reused across different products
  • No batch numbers or batch numbers that don't match product labels
  • Purity claims of 99%+ with no supporting data

What This Means for Consumers

If You're Using Research Vendors

  1. Demand third-party COAs from a named, contactable lab
  2. Verify the lab exists — search for them online, check they offer peptide testing
  3. Look for mass spec data — HPLC alone doesn't confirm identity
  4. Be skeptical of perfect numbers — real results have decimals and trace impurities
  5. Consider the price — vendors providing legitimate third-party testing charge more because testing is expensive

If You're Using a Compounding Pharmacy

You're generally in better shape. Licensed pharmacies have regulatory obligations around quality testing. But still:

  1. Ask for the COA if not provided automatically
  2. Verify PCAB accreditation or equivalent quality certification
  3. Confirm endotoxin testing for any injectable product
  4. Check that batch numbers match your dispensed product

If You're Considering the Switch

The data strongly supports the prescription pathway for anyone using peptides therapeutically. The quality assurance gap between licensed pharmacies and research vendors is not marginal — it's a chasm.

Our physician directory lists providers who prescribe peptide therapy, and our 503A vs 503B guide explains the pharmacy options.

Limitations of This Analysis

  • We evaluated COA documents, not actual product quality
  • Sample size (50) is illustrative, not statistically definitive
  • We could not verify all lab claims (some labs didn't respond to inquiries)
  • The research vendor market changes rapidly — vendors enter and exit frequently
  • Community testing data used for cross-reference may have its own quality issues

The Bigger Picture

As the PCAC meeting in July 2026 potentially opens legitimate compounding pathways for peptides like BPC-157, TB-500, and Semax, the quality landscape should improve. More licensed pharmacies entering the space means more products with proper quality documentation.

But the transition period is dangerous. Demand is high, regulatory clarity is low, and bad actors thrive in uncertainty. Until the regulatory picture stabilizes, COA verification isn't optional — it's essential.

For step-by-step COA reading instructions, see How to Read a Certificate of Analysis. For vendor-specific COA data, visit our COA Verification Database.

This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before using any peptide therapy.